Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.
RBC Capital Maintains Outperform on Sumo Logic, Lowers Price Target to $22
RBC Capital analyst Matthew Hedberg maintains Sumo Logic (NASDAQ:SUMO) with a Outperform and lowers the price target from $25 to $22.
